In a phase 2 double-blind trial, psilocybin, a synthetic compound found in psychedelic mushrooms, was investigated for its potential in treating treatment-resistant depression. Adults with this condition were randomly assigned to receive a single dose of psilocybin at 25 mg, 10 mg, or a 1 mg control, alongside psychological support. The study found that the 25 mg dose significantly reduced depression scores over three weeks compared to the 1 mg dose. However, it was associated with adverse effects, including headaches, nausea, and dizziness. Further research, including larger and longer trials comparing psilocybin with existing treatments, is needed to assess its efficacy and safety for treatment-resistant depression.
The decline of red wolf populations in eastern North Carolina, once thriving after reintroduction in 1987, prompted a study on ecosystem impacts. With a peak at 120 animals, a subsequent crash due to increased mortality and reduced support revealed correlations. Using camera traps from 2015 to 2021, the study noted increased prey and competitor species, […]
Have you ever had a dream that stayed with you long after you woke up? Did it feel like the dream was trying to tell you something? A new study published in the Academy of Management Journal suggests that dreams can have a significant impact on our work behavior. The study, titled “A Spillover Model […]
Exploring global gecko conservation in zoos, our study utilizes ZIMS and ZTL databases to assess the distribution patterns of threatened Gekkota species. Only 9.3% of recognized gecko species are kept, with 20.4% classified as threatened. While European, North American, and Australian zoos house most species, Oceania prioritizes native geckos. Breeding success is observed in 38.0% […]